159 related articles for article (PubMed ID: 8198464)
1. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.
Brewer GJ; Dick RD; Johnson V; Wang Y; Yuzbasiyan-Gurkan V; Kluin K; Fink JK; Aisen A
Arch Neurol; 1994 Jun; 51(6):545-54. PubMed ID: 8198464
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy.
Brewer GJ; Johnson V; Dick RD; Kluin KJ; Fink JK; Brunberg JA
Arch Neurol; 1996 Oct; 53(10):1017-25. PubMed ID: 8859064
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy.
Brewer GJ; Hedera P; Kluin KJ; Carlson M; Askari F; Dick RB; Sitterly J; Fink JK
Arch Neurol; 2003 Mar; 60(3):379-85. PubMed ID: 12633149
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
Brewer GJ; Askari F; Lorincz MT; Carlson M; Schilsky M; Kluin KJ; Hedera P; Moretti P; Fink JK; Tankanow R; Dick RB; Sitterly J
Arch Neurol; 2006 Apr; 63(4):521-7. PubMed ID: 16606763
[TBL] [Abstract][Full Text] [Related]
6. Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study.
Weiss KH; Askari FK; Czlonkowska A; Ferenci P; Bronstein JM; Bega D; Ala A; Nicholl D; Flint S; Olsson L; Plitz T; Bjartmar C; Schilsky ML
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):869-876. PubMed ID: 28988934
[TBL] [Abstract][Full Text] [Related]
7. Initial therapy of patients with Wilson's disease with tetrathiomolybdate.
Brewer GJ; Dick RD; Yuzbasiyan-Gurkin V; Tankanow R; Young AB; Kluin KJ
Arch Neurol; 1991 Jan; 48(1):42-7. PubMed ID: 1986725
[TBL] [Abstract][Full Text] [Related]
8. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
9. Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease.
Esmaeli B; Burnstine MA; Martonyi CL; Sugar A; Johnson V; Brewer GJ
Cornea; 1996 Nov; 15(6):582-8. PubMed ID: 8899270
[TBL] [Abstract][Full Text] [Related]
10. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment.
Brewer GJ
CNS Drugs; 2005; 19(3):185-92. PubMed ID: 15740174
[TBL] [Abstract][Full Text] [Related]
11. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
Brewer GJ
Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
[TBL] [Abstract][Full Text] [Related]
12. Development of neurologic symptoms in a patient with asymptomatic Wilson's disease treated with penicillamine.
Brewer GJ; Turkay A; Yuzbaziyan-Gurkan V
Arch Neurol; 1994 Mar; 51(3):304-5. PubMed ID: 8129644
[TBL] [Abstract][Full Text] [Related]
13. Interactions of zinc and molybdenum with copper in therapy of Wilson's disease.
Brewer GJ
Nutrition; 1995; 11(1 Suppl):114-6. PubMed ID: 7749256
[TBL] [Abstract][Full Text] [Related]
14. Atypical childhood Wilson's disease.
Carlson MD; Al-Mateen M; Brewer GJ
Pediatr Neurol; 2004 Jan; 30(1):57-60. PubMed ID: 14738953
[TBL] [Abstract][Full Text] [Related]
15. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.
Brewer GJ
J Cell Mol Med; 2003; 7(1):11-20. PubMed ID: 12767257
[TBL] [Abstract][Full Text] [Related]
16. Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease.
Karunajeewa H; Wall A; Metz J; Grigg A
Aust N Z J Med; 1998 Apr; 28(2):215-6. PubMed ID: 9612534
[No Abstract] [Full Text] [Related]
17. Treatment of Wilson's disease with zinc: XV long-term follow-up studies.
Brewer GJ; Dick RD; Johnson VD; Brunberg JA; Kluin KJ; Fink JK
J Lab Clin Med; 1998 Oct; 132(4):264-78. PubMed ID: 9794697
[TBL] [Abstract][Full Text] [Related]
18. [Wilson's disease with severe neurological manifestations: response to trientine plus zinc therapy].
Serra B; Primo J; García M; Amorós I; Aragó M; Merino C
Gastroenterol Hepatol; 2004 May; 27(5):307-10. PubMed ID: 15117609
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc.
Askari FK; Greenson J; Dick RD; Johnson VD; Brewer GJ
J Lab Clin Med; 2003 Dec; 142(6):385-90. PubMed ID: 14713890
[TBL] [Abstract][Full Text] [Related]
20. Clinical considerations for an effective medical therapy in Wilson's disease.
Weiss KH; Stremmel W
Ann N Y Acad Sci; 2014 May; 1315():81-5. PubMed ID: 24754532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
